As noted earlier, admission to the ICU is not a reliable surrogate for diagnosis of PASS [31]. A misclassification of patients in this cohort is further supported by the markedly low rate of separately reported, selective (undefined) OFs (respiratory failure in 10.5%), hospital

length of stay markedly lower than reported by others [27, 30], and an implausibly low hospital morality rate (0.8% among non-shock patients) [32]. Finally, in the largest cohort reported to date, Bauer et al. [33] have examined a national administrative data set in the US, focusing on PASS among delivery hospitalizations. The incidence CA4P cell line of PASS was 9 hospitalizations per 100,000 deliveries-years [33]. The broad range of reported estimates of PASS incidence in the aforementioned studies limits our understanding of the contemporary burden of severe sepsis on the obstetric population, even when Temsirolimus molecular weight considering only population-level investigations, and expected country-specific variation. As noted, varying case definitions and related methodological problems affect interpretation of the reported findings. In addition, the CHIR-99021 in vitro optimal code-based [i.e., International Classification of Diseases, Ninth Revision, Clinical

Modification (ICD-9-CM)] case definition of severe sepsis (commonly using both specific ICD-9-CM codes for severe sepsis and septic shock and a combination of sepsis/infection codes, combined with codes of OF) when using

administrative data remains unsettled, with reported incidence estimates of severe sepsis in the general population varying by as much as 3.5-fold across different coding approaches [34]. It is thus possible that the study reported by Bauer et al. [33], while using similar, more conservative, case identification approach to that in studies of severe sepsis in the general population, may have substantially underestimated the burden of PASS. Nevertheless, when different administrative case definitions of severe sepsis were used in the general population, all trended similarly over time [34]. The study by Bauer et al. [33] likely represents at present time the broadest report to date 3-mercaptopyruvate sulfurtransferase on PASS, with their findings suggesting that the incidence of PASS among women during delivery hospitalizations is markedly lower than that in the general population with severe sepsis [4]. The available contemporary reports on PASS have been restricted to Western Europe and the US. However, as noted earlier [22], the bulk of the global burden of maternal sepsis and thus of PASS is affecting disproportionately developing countries. Thus, data from developing countries (and other regions) are urgently needed to better understand the current epidemiology and the public health impact of PASS in these areas.